Open Access

Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia

Journal of Translational Medicine201614:82

https://doi.org/10.1186/s12967-016-0837-5

Received: 9 November 2015

Accepted: 1 March 2016

Published: 24 March 2016

Abstract

Background

The mechanism of action of imatinib is known to involve the Fas-mediated apoptosis pathway. Consequently inter-individual variations in this apoptosis pathway might be associated with imatinib response or resistance.

Methods

This study attempted to focus on eight genotypes in the apoptosis pathway including FAS (rs1800682, rs2229521, rs2234767 and rs2234978), FASLG (rs763110), CASP10 (rs13006529), and APAF1 (rs1439123, rs2288713) and analyzed their association with treatment outcomes including molecular response with 4.5 log reduction (MR4.5), following imatinib therapy in 187 Korean CML patients.

Results

The GG/GA genotype in FAS (rs2234767) showed a higher rate of MR4.5 than the AA genotype (at 5 years 59.7 vs 37.4 %, p = 0.013). Using a bootstrap procedure for internal validation we confirmed that FAS (rs2234767) correlates with MR4.5 (p = 0.050). Multivariate analysis confirmed that the FAS genotype (rs2234767) is an independent surrogate for MR4.5 (p = 0.019, HR 0.43, 95 % CI [0.22–0.87]).

Conclusions

The Fas/FasL signaling pathway may represent the major pathway that mediates apoptosis in CML treated with imatinib. SNP markers in the apoptosis pathway including FAS genotype (rs2234767) can be potential surrogates for predicting deeper molecular response after imatinib therapy.

Keywords

Single nucleotide polymorphismsImatinibChronic myeloid leukemiaApoptosis pathway

Background

Chronic myeloid leukemia (CML) is a clonal disorder characterized by the Philadelphia (Ph) chromosome as a result of translocation of chromosome 9 and 22, t(9; 22) (q34; q11) [1]. The molecular consequence of this translocation is rearrangement of the BCR-ABL1 oncogene that encodes the chimeric bcr-abl1 protein with constitutive kinase activity [1]. This leads to increased proliferation and enhanced survival of leukemic stem cells (LSCs) [2]. The bcr-abl1 fusion protein enhances cell survival and exerts antiapoptotic activity in CML cells, thus mediating resistance to apoptosis [38]. Bcr-abl1 induces Bcl-XL, an antiapoptotic protein, through STAT5 phosphorylation [9]. The bcr-abl1 fusion protein also blocks the mitochondrial release of cytochrome C, exerting anti-apoptotic activity [10, 11] and inhibits other proapoptotic proteins including Bad or Bim [1215].

Imatinib is a specific Abl-tyrosine kinase inhibitor that inhibits cellular growth and induces apoptosis in CML [16]. Once imatinib binds to the bcr-abl1 oncoprotein, it inactivates the kinase activity and subsequent signal transduction pathway resulting in apoptosis [1719]. Imatinib can also restore Bad and Bim, which are inhibited by the bcr-abl1 fusion protein [1215]. The primitive quiescent Philadelphia positive LSCs are relatively insensitive to imatinib or other tyrosine kinase inhibitors (TKIs) [20, 21], so it is extremely difficult to eradicate them with imatinib or other TKIs.

The Fas-mediated apoptosis pathway plays an important role in imatinib’s mechanism of action. Cells undergo apoptosis in response to signals through several different mechanisms including the Fas receptor (Fas-R) pathway. The Fas-R is expressed on hematopoietic stem cells (HSCs) in CML patients [22]. The Fas-induced pathway can trigger apoptotic signals to both normal HSCs and CML cells [22]. The Fas-R is upregulated by IFN-gamma and TNF-alpha on CD34+ cells and by IFN-alpha [23]. A recent study demonstrated that IFN-alpha treatment promotes proliferation of dormant HSCs, increasing the chance of G0 cells entering into the active cell division cycle [24]. IFN-alpha increases cell death in CML patients through the Fas-mediated apoptosis pathway by increasing Fas-R expression on LSCs and increasing their exposure to cytotoxic therapy including TKIs.

We postulated that inter-individual variation in the apoptosis pathway might be associated with imatinib response or resistance particularly in relation to the depth of molecular response (4.5 log reduction or MR4.5), which reflects LSC clearance by TKI therapy. We also attempted to identify predictive/prognostic genetic markers in CML patients treated with imatinib. In the current study, candidate genotypes were selected based on the literature. For SNP information was not available in the literature, SNPs were selected using the criteria of synonymous or non-synonymous SNP in exon region with minor allele frequency >1 %. We examined 8 apoptosis-associated SNPs and analyzed their association with response and resistance to imatinib in 187 Korean CML patients.

Methods

Study population

This study was performed according to the declaration of Helsinki. The study protocol was approved by the Institutional Research Board of the Sungkyunkwan University School of Medicine, Seoul, Korea. The study included 187 consecutive CML patients who started imatinib therapy between March 2002 and December 2008 in three centres in Korea with samples available for genotyping. Clinical information was obtained by retrospective medical chart review. Informed written consents were obtained from the participants in accordance with the requirements of the institutional Research Board of the Sungkyunkwan University School of Medicine. Biospecimens for genotyping were obtained from archived marrow or peripheral blood samples taken at the time of diagnosis.

Patient evaluation and disease monitoring

Prior to imatinib therapy all patients had routine history taken, a physical examination, a complete blood count, standard baseline biochemistry tests and bone marrow evaluation for morphology, conventional cytogenetic analysis, and BCR/ABL mRNA RT-PCR. Cytogenetic analysis was performed using the G-banding technique. Patients were monitored regularly on an out-patient basis as follows: biweekly physical examinations, blood counts, and biochemistry were obtained during the first month of imatinib therapy, then monthly until a cytogenetic response was achieved, and then every 3 months thereafter. Bone marrow evaluation and/or FISH studies were performed every 3 months until a complete cytogenetic response was confirmed. Quantitative BCR/ABL mRNA PCR on peripheral blood was repeated every 3–4 months regardless of cytogenetic response. This was performed according to the manufacturer’s instructions using ABI 7900 Thermal Cycler (Applied Biosystems, Foster City, CA, USA). ABL1 gene was used as a reference. The BCR-ABL1 transcript level data was retrospectively compared and validated with those using Light Cycler. Standardization procedure to international scale was conducted per recommendation [25]. Sensitivity of the assay was up to 4.5 log reduction with minimum number of reference gene transcripts of 32,000 copies ABL1. Abl1 tyrosine kinase domain mutations were screened in any patient in an advanced phase of disease. Mutation screening was indicated in patients on imatinib who had evidence of treatment failure, loss of response or disease progression.

Sequenom massARRAY genotyping system

Candidate genotypes were selected as synonymous or non-synonymous SNPs in exon regions with a minor allele frequency over 0.01 or based on the literature review. If the frequency was not available, it was sourced from the Entrez SNP site (http://www.ncbi.nlm.nih.gov/sites/entrez). The study included eight SNPs in the apoptosis pathway (Table 1), and their linkage disequilibrium plot is illustrated in Additional file 1: Figure S1.
Table 1

Summary of the candidate gene single nucleotide polymorphisms involved in the apoptosis pathway

Gene

Gene description

Chromosome

SNP ID

Allele (m/M)

Call rate (%)

MAF

HWE p value

APAF1

Apoptotic peptidase activating factor 1

12

rs1439123

C/T (Intron)

100

0.04

1.00

12

rs2288713

G/T (Intron)

100

0.27

0.71

CASP10

Caspase 10, apoptosis-related cysteine peptidase

2

rs13006529

A/T (Leu → Ile)

100

0.18

1.00

FASLG

Fas ligand (TNF receptor superfamily member 6)

1

rs763110

T/C

98.4

0.29

0.98

FAS

Fas cell surface death receptor

10

rs1800682

T/C (Intron)

93.6

0.48

0.002

10

rs2229521

G/A(Thr → Thr)

100

0.01

1.00

10

rs2234767

A/G (Ala → Thr)

100

0.47

0.02

10

rs2234978

T/C (Thr → Thr)

99.5

0.02

1.00

m minor allele, M major allele, MAF minor allele frequency, HWE Hardy–Weinberg equilibrium

First, genotyping was undertaken using the Sequenom® iPLEX platform™, according to the manufacturer’s instructions (http://www.sequenom.com; Sequenom Inc, San Diego, CA, USA). DNA was extracted using the QIAGEN DNA purification Kit (Gentra Systems Inc, Minneapolis, MN, USA). We detected SNPs by analysis of primer extension products generated from previously amplified genomic DNA using a Sequenom chip-based matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry platform. Multiplex SNP assays were designed using SpectroDesigner software (Sequenom). Ninety-six well plates containing 2.5 ng DNA in each well were amplified by PCR following the specifications of Sequenom. Unincorporated nucleotides in the PCR product were deactivated using shrimp alkaline phosphatase. Allele discrimination reactions were performed by adding extension primer(s), DNA polymerase, and a cocktail mixture of deoxynucleotide triphosphates and di-deoxynucleotide triphosphates to each well. Mass Extend clean resin (Sequenom) was added to the mixture for removal of extraneous salts that might interfere with MALDI-TOF analysis. Primer extension products were then cleaned and spotted onto a SpectroChip. Genotypes were identified by spotting an aliquot of each sample onto a 96 SpectroChip (Sequenom), which was subsequently read by a MALDI-TOF mass spectrometer. Duplicate samples and negative controls were included for evaluation of genotyping quality. Primer sequences are listed in Additional file 1: Table S1. Genotyping was performed at Bioneer inc., Chung won, Korea.

Definition of response criteria and end points

Previously defined response criteria to imatinib were used [2628]. The response was determined retrospectively through chart review. A hematologic response was defined as normalized peripheral blood cell counts (WBC <10 × 109/L and platelet <450 × 109/L) without evidence of peripheral blasts, promyelocytes, or myelocytes, and without evidence of extramedullary disease including disappearance of palpable splenomegaly lasting for at least 4 weeks. Cytogenetic responses were categorized as complete (CCR; 0 % Ph+ cells in marrow by conventional cytogenetics or FISH), partial (1–34 % Ph+ cells in marrow), or minor (35–65 % Ph+ cells in marrow). A major cytogenetic response (MCR) was defined as the sum of CCR and partial cytogenetic response (0–34 % Ph+ cells in marrow). A major molecular response (MMR) was defined as less than 0.1 % of the BCR/ABL fusion gene transcript level on an international scale by quantitative PCR, and molecular response with 4.5 log reduction (MR4.5) was defined as disappearance of detectable BCR/ABL fusion gene transcripts, equivalent to less than 0.0032 % on the international scale.

Time to treatment failure (TF) was defined as the interval between initiation of imatinib therapy and occurrence of imatinib failure, including primary and secondary resistance, (i.e. loss of response (LOR). Time of LOR was defined as the interval between the date of any confirmed response (i.e. at least partial CR or deeper response) and the date at which criteria for response were no longer being met, including: transformation from chronic phase (CP) to accelerated phase (AP) or blastic crisis (BC), loss of CCR/MCR, and development of the Abelson tyrosine kinase domain mutation. Time to progression free survival (PFS) was defined as the interval between initiation of imatinib therapy and confirmation of progression to AP or BC, or death from any cause, while overall survival (OS) was defined as time from initiation of imatinib therapy until time of death from any cause or time of last follow-up. Primary resistance includes primary hematologic or cytogenetic response while secondary resistance includes loss of MCR/CCR, development of progression to advanced disease as well as development of TKD mutation.

Statistical analysis

The candidate SNPs were primarily evaluated for adequacy of Hardy–Weinberg Equilibrium (HWE) using the Chi square test. HWE and genotype frequencies were calculated using Haploview software version 4.2 (Broad Institute, Cambridge, MA; available at http://www.broadinstitute.org/scientific-community/science/programs/medical-and-population-genetics/haploview/haploview).

Cumulative incidences of MCR, CCR, MMR, and MR4.5 were calculated consideration discontinuation of imatinib as a competing risk. Probabilities of freedom from LOR and TF were estimated and plotted using the Kaplan–Meier method. Probabilities of OS and PFS were also estimated using the Kaplan–Meier method. In univariate analyses, treatment outcomes, such as MCR, CCR, MMR, MR4.5, LOR, TF, PFS, and OS were compared using log-rank tests. Multivariate analysis was performed with variables including age, prior treatment, additional cytogenetic abnormalities, disease stage (CP versus AP/BC) and significant genotypes in the univariate analyses. The multivariate analyses using Cox’s proportional hazard models were conducted using an enter model and a p value for the likelihood ratio test of >0.05.

For validation of the genetic effect, we performed internal validation using a bootstrap algorithm. Bootstrap is a resampling technique which creates bootstrap data sets by sampling with replacement. It gave us a nonparametric maximal likelihood estimate of the prediction error and can correct for the bias of the estimate and therefore avoid the need for cross-validation. We applied bootstrap based on 1000 replications, and the results are presented as the bootstrap hazard ratio (HR), confidence intervals and p values of the genetic effects. All statistical tests were two-sided with the significance level set as 0.05.

The prognostic stratification value was assessed by the likelihood ratio test (LRT) using the Cox proportional hazard regression model for MR4.5 as the endpoint to measure how well the risk score performs in predicting future clinical events. The log likelihood ratio test evaluates superiority of a prognostic stratification system over another. Two multivariate models were compared: one with only clinical risk factors, and another using clinical risk factors as well as genotype data. All the above statistical tests were performed using SAS version 9.1 (SAS Institute, Cary NC, USA) and EZR (http://www.jichi.ac.jp/saitama-sct/SaitamaHP.files/statmedEN.html).

Results

Patient and disease characteristics and imatinib treatment outcomes

Patient demographic and disease characteristics are presented in Table 2. In total, 187 CML patients were included in the study. The median age was 49 years (range 11–87). One hundred and sixty nine patients (90 %) were in CP, 11 (6 %) in AP, and 7 (4 %) in BC. The median follow-up time was 41.7 months (range 1–98.1). Incidences of MCR at 6 months, CCR at 12 months, MMR at 18 months and MR4.5 at 3 years were 43.9, 63.1, 45.3 and 44.0 % respectively. Of the 187 patients, 53 had evidence of treatment failure, and 16 LOR.
Table 2

Summary of patient demographic and disease characteristics as well as treatment outcomes in 187 CML patients treated with imatinib

Characteristics

Variables

No of pts (%)

Gender

Female

79 (42)

Male

109 (58)

Age

(Years, median, range)

49.0 (11–87)

Follow-up duration

(Months, median, range)

41.7 (0–98.1)

Cytogenetics at diagnosis

t(9;22) only

153 (81)

Additional abnormalities*

27 (15)

Unknown

7 (4)

Sokal risk group at diagnosis

Low

59 (32)

Intermediate

69 (37)

High

42 (22)

Unknown

17 (9)

Disease stage at imatinib therapy

CP

169 (90)

AP

11 (6)

BC

7 (4)

Previous treatment (any)

De novo

145 (77.5)

Previously treated

42 (22.5)

Previous treatment prior to imatinib

Interferon-alpha

30 (16.0)

Duration of imatinib therapy

Median in months (range)

36.9 (0–98.1)

AP accelerated phase, BC blastic crisis, CP chronic phase

* Additional cytogenetic abnormalities: t(9; 22; 11) (n = 1); t(7; 9; 22) (n = 1); t(9; 22; 17) (n = 1); t(9; 22; 19) (n = 1); t(4; 22) with t(17; 20) (n = 1); inv(3) (n = 2); der(9) (n = 1); der(9), del(9) (n = 1); del(22q) (n = 1); +der(22) (n = 3); −Y(n = 1); +8(n = 1); −12 (n = 1); 92, idemx2(n = 3); 69, XXX with 92, XXXX and 138, XXXXXX (n = 1), t(8;9;22) (n = 1); dup(1) (n = 1)

Univariate analysis of candidate SNPs in the apoptosis pathway

Details of the eight candidate SNPs are summarized in Table 1 and Additional file 1: Table S1. There is a strong linkage disequilibrium between the SNPs in FAS (r2 = 1; rs2234767 and rs1800682), presented in Additional file 1: Figure S1.

The patient clinical characteristics, treatment history prior to imatinib, initial imatinib dose, disease stage and sokal risk score all correlated with responses to imatinib. In univariate analysis, patients who had prior treatment showed a lower probability of achieving MCR (p = 0.009), CCR (p = 0.016), MMR (p = 0.002), and MR4.5 (p = 0.011), and had a shorter time to TF (p = 0.039). Patients with a high sokal risk score showed a lower probability of achieving CCR (p = 0.050) and a shorter time to TF (p = 0.003) (Additional file 1: Table S2).

The results of univariate analyses for treatment outcomes with imatinib are presented in Table 3. The GG/GA versus AA FAS genotypes (rs2234767) showed rates of MR4.5 at 5 years of 59.7 ± 4.7 % (49.7–68.3 %) vs 37.4 ± 10.6 % (16.6–58.3 %) respectively (p value = 0.013, Hazard ratio 0.423, 95 % confidence interval [95 % CI 0.229–0.781]; Fig. 1b). The CC FAS genotype (rs1800682) also showed a lower MR4.5 rate than other genotypes (p = 0.032; Table 3 and Fig. 1). The incidence of MR4.5 at 5 years in the TT/TC FAS genotype (rs1800682) was 58.8 ± 5.1 % (48.2–68.0 %) vs 42.2 ± 10.0 % (22.1–61.3 %) in the CC genotype (HR 0.508, 95 % CI [0.291–0.886]; Fig. 1a).
Table 3

Summary of results of the univariate analysis for treatment outcomes based on the candidate genotypes in the apoptosis pathway

Gene

SNP ID

Referent genotype

Adverse genotype

MCR

CCR

MMR

MR4.5

LOR

TF

PFS

OS

APAF1

rs1439123

CC/CT

TT

0.803

0.393

0.233

0.085

0.011*

0.323

0.510

0.939

APAF1

rs2288713

GG/TG

TT

0.747

0.886

0.617

0.530

0.812

0.992

0.271

0.863

CASP10

rs13006529

AA/TA

TT

0.250

0.433

0.513

0.671

0.144

0.025*

0.311

0.019*

FASLG

rs763110

TT/TC

CC

0.414

0.186

0.017*

0.123

0.145

0.097

0.001**

0.020*

FAS

rs1800682

TT/TC

CC

0.871

0.354

0.251

0.032*

0.086

0.129

0.428

0.863

FAS

rs2229521

GG/GA

AA

0.856

0.688

0.748

0.863

0.600

0.384

0.600

0.685

FAS

rs2234767

GG/GA

AA

0.944

0.259

0.179

0.013*

0.034*

0.093

0.374

0.978

FAS

rs2234978

TT/TC

CC

0.026*

0.036*

0.050*

0.011*

0.379

0.089

0.409

0.535

SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 complete molecular response, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)

** p < 0.01/* p < 0.05

Fig. 1

Incidence of MR4.5 based on the FAS (rs1800682) (a) and FAS (rs2234767) (b) genotypes

In the case of CASP10 (rs13006529), the TT genotype correlated with a lower risk of TF and a longer OS than the TA/AA genotype (Table 3). The probability of freedom from TF at 5 years in the TT genotype, was 71.5 ± 4.7 % (61.2–79.5 %), vs 59.6 ± 6.6 % (45.2–71.2 %) in the TA or AA genotypes (p = 0.025, HR 0.543, 95 % CI [0.317–0.932]; Fig. 2).
Fig. 2

Probability of freedom from treatment failure based on the CASP10 genotype (13006529)

Patients with the CC FASLG genotype (rs763110) showed a higher MMR rate, and a longer PFS and OS compared to the TT/TC genotype (Table 3 and Fig. 3): MMR at 18 months of 51.0 ± 5.4 % (39.9–61.0 %) vs 35.6 ± 5.1 % (25.6–45.7 %), p = 0.017; PFS of 98.7 ± 2.2 % (91.0–99.8 %) vs 77.7 ± 6.0 % (63.3–87.0 %), p = 0.001; and OS at 5 years of 98.6 ± 2.4 % (90.5–99.8 %) vs 89.5 ± 4.2 % (78.7–95.0 %) p = 0.020.
Fig. 3

Differences in MMR (a), PFS (b) and OS (c) based on the FASLG genotype (rs763110)

In FAS (rs2234978), the TT/TC genotype showed a higher rate of MCR (p = 0.026), CCR (p = 0.036), MMR (p = 0.050) and MR4.5 (p = 0.011) compared to those with the CC genotype (Table 3).

Internal validation using a bootstrap procedure confirmed the significance of the correlation between FAS genotype and MR4.5

The p value from the bootstrap procedure was significant at 0.050 (95 % CI [0.000–0.221]), confirming that the FASGG/GA genotype (rs2234767) was associated with a higher MR4.5 rate compared to the AA genotype (HR 0.431, 95 % CI [0.219–0.682]; Table 4).
Table 4

Internal validation using a Bootstrap procedure with 1000 replications

Parameter

Gene

SNP ID

Bootstrap p value (95 % CI)

MCR

FAS

rs2234978

0.138 (0.000–0.605)

CCR

FAS

rs2234978

0.187 (0.000–0.727)

MMR

FASLG

rs763110

0.065 (0.000–0.351)

FAS

rs2234978

0.178 (0.000–0.762)

MR4.5

FAS

rs1800682

0.497 (0.053–0.951)

FAS

rs2234767

0.050 (0.000–0.221)*

FAS

rs2234978

0.073 (0.000–0.345)

LOR

APAF1

rs1439123

0.142 (0.000–0.749)

FAS

rs2234767

0.169 (0.000–0.783)

TF

CASP10

rs13006529

0.102 (0.000–0.563)

PFS

FASLG

rs763110

0.365 (0.003–0.992)

OS

CASP10

rs13006529

0.162 (0.002–0.991)

FASLG

rs763110

0.424 (0.017–0.994)

MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 complete molecular response, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, HNF4A hepatocyte nuclear factor 4, alpha, APAF1 apoptotic peptidase activating factor 1, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)

* P ≤ 0.05

Multivariate analyses confirming FAS genotype (rs2234767) as an independent predictor for MR4.5

Multivariate analysis was performed in order to confirm that the candidate SNP is an independent risk factor for clinical outcomes after adjustment for other clinical risk factors including age, prior treatment, additional cytogenetic abnormalities and disease stage.

Analysis revealed that the patients with the FAS AA genotype (rs2234767) showed a lower probability of achieving MR4.5 (p = 0.019, HR 0.43, 95 % CI [0.22–0.87]) than those with the GG/GA genotype, and that those with the CC genotype (rs2234978) had a lower probability of MR4.5 (p = 0.003 HR 0.45, 95 % CI [0.26–0.77]) than those with the CC genotype (Table 5).
Table 5

Results of multivariate analyses

Risk factor

Referent parameter

Adverse parameter

Univariate p value

Multivariate p value

HR (95 % CI)

MCR

 FAS (rs2234978)

CT/TT

CC

0.026

0.062

0.52 (0.26–1.03)

 Age, continuous

0.748

0.920

1.00 (0.99–1.01)

 Prior treatment

No

Yes

0.009

0.060

0.56 (0.30–1.03)

 ACA

Absent

Present

0.128

0.560

0.85 (0.50–1.45)

 Disease stage

AP/BC

CP

0.450

0.190

1.98 (0.72–5.46)

CCR

 FAS (rs2234978)

CT/TT

CC

0.036

0.100

0.56 (0.28–1.12)

 Age, continuous

0.796

0.910

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.016

0.074

0.57 (0.31–1.05)

 ACA

Absent

Present

0.496

0.330

0.77 (0.45–1.30)

 Disease stage

AP/BC

CP

0.399

0.060

2.48 (0.96–6.38)

MMR

 FAS (rs2234978)

CT/TT

CC

0.050

0.022*

0.53 (0.30–0.91)

 FASLG (rs763110)

CT/TT

CC

0.017

0.079

1.42 (0.96–2.11)

 Age, continuous

0.670

0.880

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.002

0.007**

0.44 (0.24–0.80)

 ACA

Absent

Present

0.097

0.490

0.81 (0.44–1.48)

 Disease stage

AP/BC

CP

0.235

0.062

2.48 (0.96–6.44)

MR4.5

 FAS (rs2234767)

GA/GG

AA

0.013

0.019*

0.43 (0.22–0.87)

 FAS (rs2234978)

CT/TT

CC

0.011

0.003**

0.45 (0.26–0.77)

 Age, continuous

0.911

0.470

0.99 (0.98–1.01)

 Prior treatment

No

Yes

0.011

0.051

0.50 (0.25–1.00)

 ACA

Absent

Present

0.110

0.930

0.97 (0.46–2.02)

 Disease stage

AP/BC

CP

0.316

0.110

3.17 (0.76–13.17)

LOR

 APAF1 (rs1439123)

TT

CT/CC

0.011

0.174

0.36 (0.08–1.57)

 FAS (rs2234767)

GA/GG

AA

0.034

0.177

2.21 (0.70–7.02)

 Age, continuous

 

0.875

0.99 (0.96–1.03)

 Prior treatment

No

Yes

0.062

0.538

1.47 (0.43–5.06)

 ACA

Absent

Present

0.973

0.918

1.08 (0.24–4.89)

 Disease stage

AP/BC

CP

0.432

0.607

1.77 (0.20–15.43)

TF

 CASP10 (rs13006529)

TA/AA

TT

0.025

0.049*

0.57 (0.32–0.99)

 Age, continuous

0.978

0.869

0.99 (0.97–1.02)

 Prior treatment

No

Yes

0.039

0.040*

1.94 (1.03–3.67)

 ACA

Absent

Present

0.257

0.483

1.31 (0.61–2.81)

 Disease stage

AP/BC

CP

0.001

0.093

0.47 (0.20–1.13)

PFS

 FASLG (rs763110)

CT/TT

CC

0.001

0.003**

0.04 (0.01–0.36)

 Age, continuous

0.765

0.260

0.98 (0.94–1.02)

 Prior treatment

No

Yes

0.235

0.053

3.28 (0.98–10.90)

 ACA

Absent

Present

0.093

0.018*

4.36 (1.29–14.71)

 Disease stage

AP/BC

CP

0.873

0.251

3.58 (0.41–31.68)

OS

 CASP10 (rs13006529)

TA/AA

TT

0.019

0.050*

0.25 (0.06–1.00)

 FASLG (rs763110)

CT/TT

CC

0.020

0.046*

0.12 (0.01–0.97)

 Age, continuous

0.787

0.300

0.97 (0.92–1.02)

 Prior treatment

No

Yes

0.225

0.170

2.75 (0.65–11.64)

 ACA

Absent

Present

0.441

0.175

3.07 (0.61–15.51)

 Disease stage

AP/BC

CP

0.917

0.377

2.94 (0.27–32.15)

ACA additional cytogenetic abnormality, HR hazard ratio, SNP single nucleotide polymorphism, MCR major cytogenetic response, CCR complete cytogenetic response, MMR major molecular response, MR4.5 molecular response with 4.5 log reduction, LOR loss of response, TF treatment failure, PFS progression free survival, OS overall survival, APAF1 apoptotic peptidase activating factor 1, CASP10 caspase 10, FAS Fas cell surface death receptor, FASLG Fas ligand (TNF receptor superfamily member 6)

* P < 0.05/** P < 0.01

Patients with the CASP10 TT genotype (rs13006529) had a lower probability of freedom from TF (p = 0.049 HR 0.57, 95 % CI [0.32–0.99]) and a better OS (p = 0.050 HR 0.25, 95 % CI [0.06–1.00]) than those with the AA/TA genotype. In addition, patients with the FASLG CC genotype (rs763110) had a better PFS (p = 0.003 HR 0.04, 95 % CI [0.01–0.36]) and OS (p = 0.046 HR 0.12, 95 % CI [0.01–0.97]) than those with the TT/TC genotype. History of treatment prior to imatinib was a risk factor for TF (p = 0.040 HR 1.94, 95 % CI [1.03–3.67]) and MMR (p = 0.007 HR 0.44, 95 % CI [0.24–0.80]; Table 5).

The incorporation of genotype in addition to clinical factors in multivariate analysis improved the prognostic stratification power for MR4.5

We attempted to answer the question of whether the addition of genotype data could enhance prognostic stratification. Two multivariate models were compared: one with clinical risk factors alone, and another with additional genotype data. The log likelihood ratio test for MR4.5 showed a significant difference between the two models in favor of the model including genotype data (p = 0.006; Additional file 1: Table S3).

Discussion

Imatinib is a specific inhibitor of the bcr-abl1 fusion protein and is an example of successful targeted therapy [29]. However, it appears that the clinical response of imatinib relies on the genetic background of a patient. In this study we focused on eight SNPs involved in the apoptosis pathway. Results showed that: (1) the GG/GA FAS genotype (rs2234767) showed a higher MR4.5 rate at 5 years of 59.7 % compared to the AA genotype (37.4 %, p = 0.013); (2) an internal validation procedure confirmed that FAS (rs2234767) correlates with MR4.5 using multiple replications with a bootstrap algorithm (p = 0.050); (3) multivariate analyses confirmed that FAS genotype (rs2234767) is an independent predictor for MR4.5 even after taking into account other clinical risk factors including age, prior treatment, additional cytogenetic abnormality and disease stage (p = 0.019, HR 0.43, 95 % CI [0.22–0.87]). Recent advances in the CML treatment suggested around 40 % of patients can achieve treatment free remission without requiring active CML treatment even after stopping TKI in the patients attained deeper molecular response (defined as 4.5 log reduction of bcr-abl1 transcript or deeper) for 2 years or longer following imatinib therapy for 5 years or longer. This finding emphasized clinical importance of MR4.5 achievement as a relevant milestone for TKI discontinuation attempt [30].

Binding of Fas ligand (FasL) to its membrane receptor Fas-R induces apoptosis via a typical death receptor signaling pathway. The trimerization of Fas-R upon the binding with FasL recruits and subsequently activates Caspase 8 and 10, and these initiator caspases trigger apoptosis by activating executive Caspase 3 directly, or by activating Bid and releasing cytochrome C from mitochondria. The FasL/Fas-R signaling pathway plays an important role in both physiological and pathological conditions [31]. Fas-R is expressed constitutively in CD34+ cells in CML patients. Fas-R triggering results in a decreased proliferation rate due to apoptosis of clonogenic cells [32].

The Fas-mediated apoptosis pathway is important in imatinib’s mechanism of action. The FAS genotype (rs2234767) showed a significant and independent association with the achievement of MR4.5. Furthermore the FAS genotype showed a greater correlation with MR4.5 than other clinical parameters, probably because the Fas-mediated apoptosis pathway is more significant in CD34+/CD38− LSCs compared to differentiated hematopoietic cells, a parameter reflecting LSC burden after imatinib therapy.

The two SNPs in FAS, rs2234767 (GG/GA vs AA) and (rs1800682; TT/TC vs CC) that had a strong association with MR4.5 are functional polymorphisms in the FAS promoter region. The A to G transition at rs1800682 in the enhancer region, modulates the signal transducer and activator of transcription (STAT-1), thus diminishing promoter activity and resulting in down-regulation of Fas expression [33]. The G to A substitution at rs2234767 in the silencer region of the FAS gene is reported to be associated with cancer risk, so that the AA genotype increases the risk of cancer, while the G-allele is a protective factor [34]. In this study, the G allele increased the rate of MR4.5 compared to the A allele. This suggests that the G-allele may result in higher Fas expression that correlates with a better response to imatinib therapy.

Other genotypes also showed potential correlations with clinical outcomes of imatinib therapy. The CASP10 genotype (rs13006529) which encodes an immediate downstream apoptotic initiator CASP10 was associated with treatment failure. Although this SNP lacks functional validation it is known to be significantly associated with cancer risk [35]. Also, SNPs in FASLG, rs763110 (CC vs TC + TT) showed a strong association with MMR, PFS and OS. These SNPs are located within a putative binding motif in the CAAT/enhancer-binding protein β transcription factor. Higher expression of FASLG is associated with the C allele compared to the T allele, thus the polymorphism may affect FasL expression and therefore FasL/Fas signaling [36].

One limitation of this study is that we only analyzed the association between these SNPs and outcomes of imatinib in Korean patients. As the genetic backgrounds among different ethnic populations may differ significantly, other SNPs in these genes and others involved in the apoptosis pathways may also be relevant to the efficacy of imatinib treatment in those groups and would need to be investigated further. In conclusion, treatment outcomes of imatinib therapy in CML patients correlate well with genetic variants in the apoptosis pathway. The Fas/FasL signaling pathway may represent the major pathway that mediates apoptosis in CML treated with imatinib. The response to imatinib, particularly MR4.5, was strongly associated with the FAS genotype (rs2234767) which was confirmed in multivariate analyses and also validated using a Bootstrap procedure. These apoptosis-associated SNPs can be used as predictive/prognostic markers for imatinib treatment in CML patients allowing more risk adaptive strategies in patients at risk of treatment failure. Furthermore, additional strategies that enhance the Fas/FasL signaling pathway with imatinib may increase its clinical efficacy. The weakness of the present study is lack of replication data using an independent set of patients. Accordingly, validation of the current results will be needed in an independent set of patients with different ethnicities in order to reach clear conclusion on the issue. Further study is also necessary to identify the functional aspects of these SNPs in relation to the mechanism of action of imatinib, especially in LSCs and to identify variations in different ethnic groups.

Conclusions

In summary, we analyzed the association between SNPs in the Fas/FasL signaling pathway and treatment outcomes including molecular response with 4.5 log reduction (MR4.5), following imatinib therapy in 187 Korean CML patients. We identified the Fas genotype (rs2234767) as a potential independent surrogate for MR4.5 in imatinib therapy. Genetic testing and some specific SNPs are helpful for drug selection for CML patients.

Abbreviations

SNPs: 

single nucleotide polymorphisms

MR4.5: 

molecular response with 4.5 log reduction

CML: 

chronic myeloid leukemia

LSCs: 

leukemic stem cells

TKIs: 

tyrosine kinase inhibitors

HSCs: 

hematopoietic stem cells

MALDI-TOF: 

matrix-assisted laser desorption/ionization time-of-flight

CCR: 

complete cytogenetic response

MCR: 

major cytogenetic response

MMR: 

major molecular response

TF: 

treatment failure

LOR: 

loss of response

CP: 

chronic phase

AP: 

accelerated phase

BC: 

blastic crisis

PFS: 

progression free survival

OS: 

overall survival

HWE: 

Hardy–Weinberg Equilibrium

HR: 

hazard ratio

LRT: 

likelihood ratio test

Declarations

Authors’ contributions

Conception and design: DK, JC, CWJ. Development of methodology: JHL, DK, JC, CWJ. Acquisition of data: HK, JHM, SKS, CWJ, DK. Analysis and interpretation of data: QZ, DK, JC. Writing, review and/or revision of the manuscript: QZ, DK, JC, NH, JHL. Administrative, technical, or material support: HK, JHM, SKS, CWJ, DK, QZ, JC. Study supervision: DK, JC, CWJ. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent to publish

All individual participants included in the study consented to publish.

Ethics, consent and permissions

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Research Board of the Sungkyunkwan University School of Medicine, Seoul, Korea, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
(2)
Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University
(3)
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto
(4)
Department of Medicine, University of Toronto
(5)
Department of Hematology/Oncology, Chonnam National University Hwasun Hospital, Chonnam National University
(6)
Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University
(7)
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine

References

  1. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(7):973–88. doi:10.4065/81.7.973.View ArticlePubMedGoogle Scholar
  2. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7(6):441–53. doi:10.1038/nrc2147.View ArticlePubMedGoogle Scholar
  3. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, Akhtar AJ, Hilton J, Jones RJ. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86(3):1148–58.PubMedGoogle Scholar
  4. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83(8):2038–44.PubMedGoogle Scholar
  5. Cotter TG. BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia. Leuk Lymphoma. 1995;18(3–4):231–6. doi:10.3109/10428199509059612.View ArticlePubMedGoogle Scholar
  6. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83(5):1179–87.PubMedGoogle Scholar
  7. McGahon AJ, Brown DG, Martin SJ, Amarante-Mendes GP, Cotter TG, Cohen GM, Green DR. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: characterization of the apoptotic death. Cell Death Differ. 1997;4(2):95–104. doi:10.1038/sj.cdd.4400213.View ArticlePubMedGoogle Scholar
  8. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR. Regulation of the Fas apoptotic cell death pathway by Abl. J Biol Chem. 1995;270(38):22625–31.View ArticlePubMedGoogle Scholar
  9. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191(6):977–84.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 1998;91(7):2415–22.PubMedGoogle Scholar
  11. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91(5):1700–5.PubMedGoogle Scholar
  12. Neshat MS, Raitano AB, Wang HG, Reed JC, Sawyers CL. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20(4):1179–86.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Salomoni P, Condorelli F, Sweeney SM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood. 2000;96(2):676–84.PubMedGoogle Scholar
  14. Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther. 2007;6(6):912–9.View ArticlePubMedGoogle Scholar
  15. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006;103(40):14907–12. doi:10.1073/pnas.0606176103.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451–64. doi:10.1056/NEJMra020777.View ArticlePubMedGoogle Scholar
  17. Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148. Cell Death Differ. 1998;5(8):710–5. doi:10.1038/sj.cdd.4400400.View ArticlePubMedGoogle Scholar
  18. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood. 2000;96(3):1070–9.PubMedGoogle Scholar
  19. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90(9):3691–8.PubMedGoogle Scholar
  20. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319–25.View ArticlePubMedGoogle Scholar
  21. Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34 + CML cells. Blood. 2007;109(9):4016–9. doi:10.1182/blood-2006-11-057521.View ArticlePubMedGoogle Scholar
  22. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89(3):957–64.PubMedGoogle Scholar
  23. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34 + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85(11):3183–90.PubMedGoogle Scholar
  24. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904–8. doi:10.1038/nature07815.View ArticlePubMedGoogle Scholar
  25. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37. doi:10.1182/blood-2006-01-0092.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–7. doi:10.1056/NEJM200104053441401.View ArticlePubMedGoogle Scholar
  27. Kantarjian HM, Talpaz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913–23.View ArticlePubMedGoogle Scholar
  28. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European L. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809–20. doi:10.1182/blood-2006-02-005686.View ArticlePubMedGoogle Scholar
  29. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87(5):543–52. doi:10.1038/clpt.2009.297.View ArticlePubMedGoogle Scholar
  30. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Intergroupe Francais des Leucemies Myeloides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35. doi:10.1016/S1470-2045(10)70233-3.View ArticlePubMedGoogle Scholar
  31. Legros L, Ebran N, Stebe E, Rousselot P, Rea D, Cassuto JP, Mahon FX, Hueber AO. Imatinib sensitizes T-cell lymphocytes from chronic myeloid leukemia patients to FasL-induced cell death: a brief communication. J Immunother. 2012;35(2):154–8. doi:10.1097/CJI.0b013e318243f238.View ArticlePubMedGoogle Scholar
  32. Selleri C, Maciejewski JP, Pane F, Luciano L, Raiola AM, Mostarda I, Salvatore F, Rotoli B. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 1998;92(3):981–9.PubMedGoogle Scholar
  33. Liu T, Zuo L, Li L, Yin L, Liang K, Yu H, Ren H, Zhou W, Jing H, Liu Y, Kong C. Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis. Tumour Biol. 2014;35(11):10911–8. doi:10.1007/s13277-014-2391-1.View ArticlePubMedGoogle Scholar
  34. Hashemi M, Fazaeli A, Ghavami S, Eskandari-Nasab E, Arbabi F, Mashhadi MA, Taheri M, Chaabane W, Jain MV, Los MJ. Functional polymorphisms of FAS and FASL gene and risk of breast cancer—pilot study of 134 cases. PLoS ONE. 2013;8(1):e53075. doi:10.1371/journal.pone.0053075.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Yan S, Li YZ, Zhu JW, Liu CL, Wang P, Liu YL. Role of CASP-10 gene polymorphisms in cancer susceptibility: a HuGE review and meta-analysis. Genet Mol Res. 2012;11(4):3998–4007. doi:10.4238/2012.November.26.1.View ArticlePubMedGoogle Scholar
  36. Mahfoudh W, Bouaouina N, Gabbouj S, Chouchane L. FASL-844 T/C polymorphism: a biomarker of good prognosis of breast cancer in the Tunisian population. Hum Immunol. 2012;73(9):932–8. doi:10.1016/j.humimm.2012.06.001.View ArticlePubMedGoogle Scholar

Copyright

© Zheng et al. 2016

Advertisement